I-Semaglutide yohlobo 2 lwesifo sikashukela

I-Semaglutide iyisizukulwane esisha se-GLP-1 (glucagon-like peptide-1) analogues, kanti i-semaglutide iyifomu lomthamo osebenza isikhathi eside elakhiwe ngokususelwa esakhiweni esiyisisekelo se-liraglutide, esinomthelela ongcono ekwelapheni uhlobo 2 sikashukela. I-Novo Nordisk isiqedile izifundo ze-6 Phase IIIa zomjovo we-semaglutide, futhi yathumela isicelo esisha sokubhaliswa kwezidakamizwa ngomjovo wamasonto onke we-semaglutide ku-US Food and Drug Administration (FDA) ngoDisemba 5, 2016. Isicelo Sokugunyazwa Kwezokuthengisa (MAA) siphinde sathunyelwa ku-European Medicines Agency (EMA).

Uma kuqhathaniswa ne-liraglutide, i-semaglutide inochungechunge olude lwe-aliphatic kanye nokwanda kwe-hydrophobicity, kodwa i-semaglutide iguqulwa ngeketanga elifushane le-PEG, futhi i-hydrophilicity yayo ithuthukiswa kakhulu. Ngemuva kokuguqulwa kwe-PEG, ayikwazi nje kuphela ukubopha eduze kwe-albumin, ukumboza indawo ye-enzymatic hydrolysis ye-DPP-4, kodwa futhi yehlise ukuphuma kwezinso, yelule isigamu sempilo yebhayoloji, futhi ifinyelele umphumela wokujikeleza isikhathi eside.